Cynthia Smith Acquires Shares in Spero Therapeutics
Cynthia Smith bought 10,000 shares of Spero Therapeutics on June 23, 2026.
Key Points
- Cynthia Smith purchased 10,000 shares of Spero Therapeutics, Inc. on June 23, 2026, with shares trading near $2.02 on Friday.
- Spero Therapeutics has a market cap of about $117 million, a P/E ratio of 7.48, and a 52-week range between $1.80 and $3.22.
- Vanguard Capital Management opened a new position in Spero Therapeutics with 1,799,880 shares valued at $4.2 million.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Cynthia Smith has acquired 10,000 shares of Spero Therapeutics, Inc. (NasdaqGS: SPRO) on June 23, 2026. The shares were trading around $2.02 on Friday.
Insider Buying and Selling at Spero Therapeutics, Inc.
On June 23, 2026, Cynthia Smith purchased 10,000 shares of Spero Therapeutics. This transaction was not part of a pre-planned trading scheme. Other insiders including Jackson Scott Thomas, John Pottage Jr., Milind Deshpande, Patrick V.J.J. Vink, and Frank Thomas also bought 20,000 shares each on the same day.
Other Institutional Activity in Spero Therapeutics
Vanguard Capital Management LLC opened a new position in Spero Therapeutics, acquiring 1,799,880 shares worth approximately $4.2 million. Meanwhile, Renaissance Technologies LLC reduced its holdings by 90,287 shares, leaving it with 1,189,235 shares valued at about $2.8 million. Two Sigma Investments, LP increased its stake by 513,061 shares, bringing its total to 885,631 shares valued at $2.1 million.
Spero Therapeutics, Inc. Stock Up 68.3%
Shares of Spero Therapeutics, Inc. traded near $2.02 on Friday. The company has a market cap of approximately $117 million and a P/E ratio of 7.48. Its stock has seen a 52-week low of $1.80 and a high of $3.22. The 50-day moving average is $2.63, while the 200-day moving average stands at $2.40. Spero boasts a strong current ratio of 10.50 and a quick ratio of 10.23.
$SPRO stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On January 30, 2025, HC Wainwright & Co. reiterated its buy rating for Spero Therapeutics with a price target of $5. Evercore ISI Group downgraded the stock to hold with a $5 target on December 20, 2024. The consensus rating for Spero is hold, with an average target price of $4 based on one analyst's opinion.
About Spero Therapeutics
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. It focuses on developing novel treatments for multi-drug resistant bacterial infections and rare diseases. The company is known for its product candidate Tebipenem HBr, an oral antibiotic for complicated urinary tract infections. Spero has partnerships with Meiji Seika Pharma and Everest Medicines to commercialize its treatments in various regions.
Bottom Line
Cynthia Smith's recent purchase of Spero Therapeutics shares highlights ongoing insider interest in the company. With a solid market cap and a low P/E ratio, Spero remains an intriguing player in the biotechnology sector. Investors should note that insider transactions like these are reported after the fact and may not reflect current market positions.
Get Spero Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SPRO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.